RxDoctor Payments Data

Jeremy Gililland, MD

Orthopaedic Surgery · Salt Lake City, UTNPI 1881849669

Payments from drug & device makers

What this record shows

The money is spread across several categories — royalties or licence payments (56.9%), other and consulting fees — rather than concentrated in one kind of arrangement. Stryker accounts for 60.7% of it on its own, with 14 other manufacturers making up the rest. Among orthopaedic surgery clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,873,843in general payments, 2019–2025

Across 740 payments — averaging $3883.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$1.7M
  • Zimmer Biomet$951K
  • Orthogrid Systems Inc$140K
  • Encore Medical, LP$22K
  • Convatec Inc.$7K
  • Smith+Nephew$5K
  • plus $4K from 9 others
$472,110in research payments, 2019–2025

Across 97 payments — averaging $4867.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Zimmer Biomet$442K
  • Solventum Corporation$16K
  • Medacta USA, Inc.$8K
  • Stryker$6K

What the payments were for

  • Royalty or licence$1,634,85757%
  • Consulting fees$430,36515%
  • Speaking & faculty fees$1200%
  • Travel & lodging$98,4053%
  • Food & beverage$13,5570%
  • Education$210%
  • Other$696,51724%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,873,843 in reported general payments places this provider in the 95th percentile of 221 orthopaedic surgery providers in Utah.

See all orthopaedic surgery providers in Utah

Medicare billing

Part B allowed, 2024
$238,101
Medicare patients
406
Services billed
878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib13$645
CeftriaxoneCeftriaxone Sodium12$372
Omeprazole12$79
Meloxicam20$76
Sodium Chloride0.9 % Sodium Chloride12$33
Amoxicillin15$22

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →